rct
    2018

    Long-term safety and efficacy of Mucuna pruriens in Parkinson disease: a randomised controlled trial

    Cilia R, Laguna J, Cassani E

    Published in Movement Disorders

    Key Findings

    Over 16 weeks Mucuna maintained motor benefit but caused more gastrointestinal adverse events and higher dropout than levodopa/carbidopa.

    Conclusions

    Tolerability limits long-term use.

    Limitations

    Moderate sample, open extension.

    Supplements Studied

    Over 16 weeks Mucuna maintained motor benefit but caused more gastrointestinal adverse events and dropout than levodopa/carbidopa.

    Related Health Concerns

    Parkinson's Disease

    Study Details

    Year:2018
    Sample Size:14
    Duration:16 weeks
    Quality Score:6/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.